Press

Biotech companies are expanding their workforce amid the pandemic, accentuating in 2020 the growth trend of recent years, in which staff increased by 7.6% in 2019 and accounted for 12.8% of people working in R&D in Spain as a whole. 

This year saw over €150 million in private capital invested, compared to €103 million in 2019. Publicly traded biotech firms attracted over €70 million on capital markets, up 35% from 2019

Spain is positioned as a leader and benchmark country in advanced therapies, the cornerstone for the treatment of diseases such as cancer, where 62% of clinical trials are conducted. 

BIOSPAIN will be held at the Palacio de Congresos y Auditorio de Navarra-Baluarte in Pamplona, from 27 September to 1 October 2021, following a hybrid format

Seven venture capital managers that specialize in the life sciences set up new workgroup as a key instrument for recovery

Spain is ranked 9th in scientific production in biotechnology and has the highest percentage of scientific papers in high-impact journals of any country: 83.3%

 

Given the situation caused by the Covid-19 pandemic, with the recommendations of healthcare authorities in mind and foreseeing the situations that may arise over the remainder of 2020, AseBio decided to postpone the event to 2021

The Spanish Association of Biocompanies (AseBio) has chosen the capital of Navarra to host the tenth edition of the event, which will be held from 29 September to 1 October.

Asebio Investor Day, meeting point for specialized biotechnology investment